CN101538246B - 作为pgds抑制剂的嘧啶酰胺化合物 - Google Patents

作为pgds抑制剂的嘧啶酰胺化合物 Download PDF

Info

Publication number
CN101538246B
CN101538246B CN200910138053.9A CN200910138053A CN101538246B CN 101538246 B CN101538246 B CN 101538246B CN 200910138053 A CN200910138053 A CN 200910138053A CN 101538246 B CN101538246 B CN 101538246B
Authority
CN
China
Prior art keywords
phenyl
pyrimidine
formic acid
acid amides
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200910138053.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101538246A (zh
Inventor
S·C·奥尔德斯
J·Z·姜
卢锦琪
马良
牟岚
H·R·芒森
J·S·萨博尔
S·图赖拉特奈姆
C·L·范德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auin Thurber holding Co.
Auin Thurber Limited by Share Ltd.
Aventis Saab LLC
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of CN101538246A publication Critical patent/CN101538246A/zh
Application granted granted Critical
Publication of CN101538246B publication Critical patent/CN101538246B/zh
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200910138053.9A 2005-10-04 2006-10-04 作为pgds抑制剂的嘧啶酰胺化合物 Active CN101538246B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04
US60/723,570 2005-10-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800365786A Division CN101282943A (zh) 2005-10-04 2006-10-04 作为pgds抑制剂的嘧啶酰胺化合物

Publications (2)

Publication Number Publication Date
CN101538246A CN101538246A (zh) 2009-09-23
CN101538246B true CN101538246B (zh) 2014-07-16

Family

ID=37635758

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200910138053.9A Active CN101538246B (zh) 2005-10-04 2006-10-04 作为pgds抑制剂的嘧啶酰胺化合物
CNA2006800365786A Pending CN101282943A (zh) 2005-10-04 2006-10-04 作为pgds抑制剂的嘧啶酰胺化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2006800365786A Pending CN101282943A (zh) 2005-10-04 2006-10-04 作为pgds抑制剂的嘧啶酰胺化合物

Country Status (27)

Country Link
US (1) US8202863B2 (enExample)
EP (1) EP1937652B1 (enExample)
JP (1) JP5452925B2 (enExample)
KR (1) KR101457966B1 (enExample)
CN (2) CN101538246B (enExample)
AR (1) AR056871A1 (enExample)
AU (1) AU2006299428B2 (enExample)
BR (1) BRPI0616815A2 (enExample)
CA (1) CA2624749C (enExample)
CR (1) CR9832A (enExample)
DO (1) DOP2006000210A (enExample)
EC (1) ECSP088335A (enExample)
ES (1) ES2514471T3 (enExample)
IL (1) IL190411A (enExample)
MA (1) MA29925B1 (enExample)
MY (1) MY151172A (enExample)
NO (1) NO20082000L (enExample)
NZ (1) NZ567208A (enExample)
PE (2) PE20070589A1 (enExample)
RU (1) RU2420519C2 (enExample)
SG (1) SG166121A1 (enExample)
TN (1) TNSN08104A1 (enExample)
TW (1) TWI415839B (enExample)
UA (1) UA93213C2 (enExample)
UY (1) UY29840A1 (enExample)
WO (1) WO2007041634A1 (enExample)
ZA (1) ZA200802222B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006290465A1 (en) * 2005-09-15 2007-03-22 Orchid Research Laboratories Limited Novel pyrimidine carboxamides
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
MX2008013194A (es) 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
CA2679198C (en) 2007-02-26 2011-07-12 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US8222243B2 (en) 2007-08-27 2012-07-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
MX2010003864A (es) 2007-10-11 2010-06-01 Vertex Pharma Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
CA2701946A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
EP2212290B1 (en) 2007-10-11 2014-12-03 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
JP2011503072A (ja) * 2007-11-13 2011-01-27 レノビス， インコーポレイテッド イオンチャネルのリガンドとしてのアミド誘導体ならびにそれを使用する薬学的組成物および方法
JP5537159B2 (ja) * 2008-02-06 2014-07-02 Ｍｓｄ株式会社 ３位置換スルホニルピペリジン誘導体
AU2009246446B2 (en) * 2008-05-13 2014-06-26 Cayman Chemical Company, Incorporated Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase
EP2307377A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
EP2307378A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
MY154000A (en) 2008-09-22 2015-04-30 Cayman Chem Co Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2010056044A2 (ko) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
CN102341385B (zh) 2009-03-09 2014-01-15 大鹏药品工业株式会社 能够抑制前列腺素d合酶的哌嗪化合物
CA2776242C (en) * 2009-10-08 2014-09-02 Sanofi Phenyloxadiazole derivatives as pgds inhibitors
JP5677325B2 (ja) * 2010-01-22 2015-02-25 大鵬薬品工業株式会社 Ｐｇｄｓ阻害作用を有するピペラジン化合物
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
EP2615084B1 (en) 2010-09-07 2016-01-06 Taiho Pharmaceutical Co., Ltd. Prostaglandin d synthase inhibitory piperidine compounds
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
JP2015506360A (ja) * 2012-01-06 2015-03-02 ユニバーシティ・オブ・サウス・フロリダ 組成物、使用方法および処置方法
MY182403A (en) * 2012-08-24 2021-01-25 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals
AU2016370779B2 (en) 2015-12-17 2019-07-25 Astex Therapeutics Limited Quinoline-3-carboxamides as H-PGDS inhibitors
EP3429588B1 (en) * 2016-03-14 2024-09-18 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US11149035B2 (en) 2017-06-13 2021-10-19 Glaxosmithkline Intellectual Property Dfvelopment Limited Chemical compounds as H—PGDS inhibitors
WO2019084529A1 (en) 2017-10-29 2019-05-02 China Medical University ADAM9 INHIBITORS AND USES THEREOF
US20210139507A1 (en) 2017-12-13 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h pgds
AU2018413791B2 (en) * 2018-03-23 2023-05-18 Step Pharma S.A.S. Aminopyrimidine derivatives as CTPS1 inhibitors
BR112021008976A2 (pt) 2018-11-08 2021-08-03 Glaxosmithkline Intellectual Property Development Limited compostos químicos
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
JP7734129B2 (ja) 2020-06-19 2025-09-04 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害する縮環化合物
EP4232425A4 (en) * 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
AU2022394333A1 (en) * 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
CA3240926A1 (en) 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Azaindole derivative inhibiting h-pgds
EP4488271A4 (en) * 2022-02-28 2026-03-04 Japan Tobacco Inc INDAZOLE COMPOUND AND ITS PHARMACEUTICAL USE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2406856A (en) * 2003-10-07 2005-04-13 Renovis Inc Novel amide compounds as ion channel ligands and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2934543A1 (de) * 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
US7115750B1 (en) * 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
AU2003248122A1 (en) * 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
EP1553089B1 (en) * 2002-07-30 2009-09-30 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
US7531558B2 (en) * 2003-02-14 2009-05-12 Glaxo Group Limited Carboxamide derivatives
DE60303238T2 (de) * 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
JP2007518816A (ja) * 2004-01-23 2007-07-12 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び炎症性及び神経因性疼痛の治療におけるこれらの使用
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2406856A (en) * 2003-10-07 2005-04-13 Renovis Inc Novel amide compounds as ion channel ligands and uses thereof

Also Published As

Publication number Publication date
NO20082000L (no) 2008-06-09
PE20110118A1 (es) 2011-03-08
UY29840A1 (es) 2007-05-31
MA29925B1 (fr) 2008-11-03
KR101457966B1 (ko) 2014-11-04
CN101282943A (zh) 2008-10-08
CR9832A (es) 2008-06-18
US20080227782A1 (en) 2008-09-18
US8202863B2 (en) 2012-06-19
TW200812977A (en) 2008-03-16
AR056871A1 (es) 2007-10-31
EP1937652B1 (en) 2014-07-30
ZA200802222B (en) 2009-09-30
ES2514471T3 (es) 2014-10-28
IL190411A (en) 2013-09-30
DOP2006000210A (es) 2007-06-15
BRPI0616815A2 (pt) 2011-07-05
EP1937652A1 (en) 2008-07-02
AU2006299428A1 (en) 2007-04-12
IL190411A0 (en) 2008-11-03
CA2624749C (en) 2011-08-16
UA93213C2 (en) 2011-01-25
CN101538246A (zh) 2009-09-23
TNSN08104A1 (en) 2009-07-14
NZ567208A (en) 2011-03-31
CA2624749A1 (en) 2007-04-12
PE20070589A1 (es) 2007-06-22
TWI415839B (zh) 2013-11-21
JP2009510170A (ja) 2009-03-12
WO2007041634A1 (en) 2007-04-12
SG166121A1 (en) 2010-11-29
AU2006299428B2 (en) 2012-04-26
KR20080050611A (ko) 2008-06-09
ECSP088335A (es) 2008-05-30
MY151172A (en) 2014-04-30
JP5452925B2 (ja) 2014-03-26
RU2420519C2 (ru) 2011-06-10
RU2008117170A (ru) 2009-11-10

Similar Documents

Publication Publication Date Title
CN101538246A (zh) 作为pgds抑制剂的嘧啶酰胺化合物
CN101180275B (zh) 四氢吲哚酮和四氢吲唑酮衍生物
CN101421252B (zh) 作为前列腺素d2受体拮抗剂的2,6-取代的-4-单取代氨基嘧啶
JP5427769B2 (ja) Ｐｇｄｓ阻害剤としてのピリミジンヒドラジド化合物
CN101039920B (zh) 作为前列腺素d2受体拮抗剂的2,6-取代的-4-单取代的氨基嘧啶
CN105307655B (zh) 哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用
JP4808154B2 (ja) プロテインキナーゼインヒビターとして有用な組成物
JP2005517659A (ja) ピリミジンＡ２ｂ選択的アンタゴニスト化合物、それらの合成、及び使用
CN101918395B (zh) 三唑联噁二唑衍生物
CN102574786A (zh) 二氢乳清酸脱氢酶抑制剂
JP2002308875A (ja) エンドセリンの活性を調節するスルホンアミドおよびそれらの誘導体
WO2008039882A1 (en) A combination of niacin and a prostaglandin d2 receptor antagonist
KR20140072037A (ko) 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
CN102317281A (zh) 作为酪蛋白激素ⅱ(ck2)调节剂的嘧啶酮
KR101701135B1 (ko) Ｐｇｄｓ 억제제로서의 페닐옥사디아졸 유도체
CN102395584A (zh) 用于代谢疾病治疗的化合物
EP1701944A2 (en) 2-(amino-substituted)-4-aryl pyramidines and related compounds useful for treating inflammatory diseases
JP2021531335A (ja) ヒストンデアセチラーゼの二環式阻害剤
CN101495474A (zh) 可用作蛋白激酶抑制剂的噻吩-甲酰胺类
WO2022042666A1 (zh) 选择性rock2激酶抑制剂
CN102596921B (zh) 新化合物
US20100179161A1 (en) Pyrazoline derivatives for the treatment of turberculosis
HK1136162A (en) Pyrimidine amide compounds as pgds inhibitors
CN1972927A (zh) 用于治疗血脂障碍的化合物和方法
HK1139413A (en) Pyrimidine hydrazide compounds as pgds inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1136162

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1136162

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Delaware

Patentee after: Aventis Saab LLC

Address before: Delaware

Patentee before: Auin Thurber Limited by Share Ltd.

TR01 Transfer of patent right

Effective date of registration: 20160817

Address after: Delaware

Patentee after: Auin Thurber Limited by Share Ltd.

Address before: Delaware

Patentee before: Auin Thurber holding Co.

Effective date of registration: 20160817

Address after: Delaware

Patentee after: Auin Thurber holding Co.

Address before: New jersey, USA

Patentee before: AVENTIS PHARMACEUTICALS Inc.